Genetics & Genomics Frontiers — 2026-05-22
This week's genomics landscape is headlined by a major market forecast placing the global genome editing sector on a path to $55.7 billion by 2035, fresh FDA approvals across companion diagnostics, and new regulatory momentum around laboratory-developed test oversight. Several clinical-stage developments from GenomeWeb's reporting round out a busy seven days for the field.
Genetics & Genomics Frontiers — 2026-05-22
Key Highlights
Genome Editing Market Surges Toward $55.7 Billion
A new report published May 21 by Healthcare Foresights projects the global genome editing market will reach USD 55.7 billion by 2035, expanding at a compound annual growth rate (CAGR) of 17.4%. The analysis covers market segmentation, key leaders, and growth drivers across CRISPR, zinc finger nucleases, and emerging base-editing platforms.
FDA Approves First ctDNA MRD-Guided Therapy — and the CDx That Enables It
In a landmark regulatory decision reported this week by GenomeWeb, the FDA approved MRD-guided use of Genentech's Tecentriq in bladder cancer, paired with Natera's Signatera companion diagnostic. This marks the first-ever FDA approval of a ctDNA MRD-guided therapy and the first blood-based MRD test approved as a companion diagnostic, representing a major milestone for liquid biopsy in oncology.
Guardant Health's Upgraded CDx Clears FDA
Guardant Health received FDA approval for an upgraded companion diagnostic test this week. The blood-based assay collects both genomic and epigenomic information to guide treatment decisions for patients with advanced cancer, extending the clinical utility of cell-free DNA profiling beyond pure mutation detection.
Foundation Medicine CDx Gains Approval for MET-Altered Lung Cancer
The FDA also approved a Foundation Medicine tissue assay as a companion diagnostic for Tepmetko (tepotinib) in MET-altered lung cancer. Foundation Medicine had previously secured CDx approval for its FoundationOne Liquid CDx assay alongside the same therapy.
Proposed Law Would Reshape LDT Oversight
A newly proposed bill reported this week would update CLIA (Clinical Laboratory Improvement Amendments) with new provisions specifically targeting laboratory-developed test (LDT) oversight. The legislation would create tools to track the performance and validation of LDTs, and would codify a 2025 court decision affirming that LDTs are not subject to FDA oversight — a significant policy development for clinical genomics laboratories.
Delfi Diagnostics cfDNA Assay Nearly Triples Lung Cancer Screening Rates
GenomeWeb reported this week on a "first look" at the clinical utility of Delfi Diagnostics' cell-free DNA assay in lung cancer screening. In a real-world demonstration, access to the liquid biopsy test nearly tripled lung cancer screening rates among eligible patients — a striking indication of how genomics-based tools may expand cancer detection beyond current imaging paradigms.
Personalis Secures Medicare Coverage for Breast Cancer MRD Test
Personalis secured Medicare coverage for its minimal residual disease (MRD) test for breast cancer pre-surgical treatment monitoring, reported this week by GenomeWeb. Medicare coverage is a critical step toward broad clinical adoption of MRD testing in oncology.
Oxford Nanopore Previews Next-Generation RNA, Proteomics Tools
At its user meeting in London this week, Oxford Nanopore previewed a suite of new products targeting RNA analysis and high-throughput sequencing, as well as longer-term R&D goals including a new nanopore design and protein sequencing capabilities.
DNA End Motifs Predict Immunotherapy Response in Head-and-Neck Cancer
A study reported this week found that DNA end motif sequences in circulating DNA are predictive of immunotherapy response in head-and-neck cancer patients. Regional motif diversity scores provided a more granular view of genetic changes separating responders from non-responders, adding a novel dimension to liquid biopsy interpretation.
QIAGEN Partners With NVIDIA to AI-Power Bioinformatics
QIAGEN announced plans to integrate NVIDIA computing and AI into its bioinformatics platform, reported this week by GenomeWeb. The move signals accelerating convergence between high-performance computing infrastructure and genomic data analysis pipelines.
Workforce Demand for Genomics Professionals Grows
A press release published this week (May 22) highlights surging demand for professionals trained in genetics and genomics interpretation, as these disciplines become more central to clinical healthcare delivery across specialties.
Analysis
The most significant development this week is the FDA's dual approval of Genentech's Tecentriq for MRD-guided use alongside Natera's Signatera ctDNA companion diagnostic in bladder cancer. This is a watershed moment: it is the first time the FDA has approved a therapy whose use is guided by circulating tumor DNA minimal residual disease status, and the first blood-based MRD test approved as a CDx. The implications extend far beyond bladder cancer — it validates the MRD-guided treatment paradigm that oncologists and biotech developers have been building toward for nearly a decade. For liquid biopsy companies, it provides the clearest regulatory precedent yet that blood-based genomic tests can serve not just as diagnostic aids, but as gatekeepers for treatment decisions.
Compounding this, the $55.7 billion genome editing market forecast and multiple simultaneous FDA CDx approvals suggest the field is entering an era of accelerating regulatory throughput — a pipeline maturing from science to standard-of-care at pace.
What to Watch
-
LDT Oversight Legislation: The proposed bill to update CLIA with new LDT tracking provisions is one to follow closely. If passed, it would define the regulatory terrain for the thousands of laboratory-developed genomic tests in clinical use, without subjecting them to the FDA review pathway that was contested in court in 2025.
-
Oxford Nanopore Product Launches: The company's previewed RNA analysis tools and protein sequencing roadmap, teased at its London user meeting, are worth watching for formal launch timelines — particularly the new nanopore design, which could shift throughput economics for long-read sequencing.
-
Delfi Diagnostics Lung Cancer Assay Rollout: With early data showing nearly triple the screening rates versus standard-of-care, the commercial and coverage pathway for Delfi's cfDNA lung cancer screening assay will be closely watched by payers and health systems evaluating genomic screening programs.
-
Mosaic Chromosomal Alteration Research: GenomeWeb reports that mosaic chromosomal alterations have been mapped in UK Biobank blood samples — a large-scale population genomics effort with implications for understanding age-related clonal expansion and cancer risk. Follow-up studies drawing on this dataset are expected.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
